Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer

Giorgio Guazzoni, Massimo Lazzeri, Luciano Nava, Giovanni Lughezzani, Alessandro Larcher, Vincenzo Scattoni, Giulio Maria Gadda, Vittorio Bini, Andrea Cestari, Nicol Maria Buffi, Massimo Freschi, Patrizio Rigatti, Francesco Montorsi

Research output: Contribution to journalArticle

Abstract

Background: Currently available predictive models fail to assist clinical decision making in prostate cancer (PCa) patients who are possible candidates for radical prostatectomy (RP). New biomarkers would be welcome. Objective: Test the hypothesis that prostate-specific antigen (PSA) isoform p2PSA and its derivates, percentage of p2PSA to free PSA (%p2PSA) and the Prostate Health Index (PHI), predict PCa characteristics at final pathology after RP. Design, setting, and participants: An observational prospective study was performed in 350 consecutive men diagnosed with clinically localised PCa who underwent RP. Measurements: We determined the predictive accuracy of serum total PSA (tPSA), free PSA (fPSA), fPSA-to-tPSA ratio (%fPSA), p2PSA, %p2PSA, and PHI. The primary end point was to determine the accuracy of these biomarkers in predicting the presence of pT3 disease, pathologic Gleason sum ≥7, Gleason sum upgrading, and tumour volume

Original languageEnglish
Pages (from-to)455-466
Number of pages12
JournalEuropean Urology
Volume61
Issue number3
DOIs
Publication statusPublished - Mar 2012

Keywords

  • [-2]proPSA
  • Pathologic examination
  • Predictive models
  • Prostate cancer
  • Prostate health index
  • Prostate-specific antigen
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer'. Together they form a unique fingerprint.

  • Cite this